Latest / International Business with Fexingo: Global Trade, Cross-Border Deals, and Multinational Operations / How Generic Drug Tariffs Will Reshape Pharma Supply Chains
Transcript
- Lucas: So the White House announced plans this week to slap steep tariffs on imported generic drugs starting in 2028. The goal is to bring pharmaceutical production back to the US. But the economics of that are a lot messier than the soundbite suggests. Luna: When you say steep — do we have a number? What kind of tariff rate are we talking about? Lucas: The details are still fuzzy, but the proposal references a 'substantial ad valorem rate' — likely north of 25 percent, maybe tiered based on how essential the drug is. The key date is 2028, which gives manufacturers four years to adjust. That's actually a relatively long runway for trade policy. Luna: Right, but the US imports about 70 percent of its generic drugs by volume. Most of that comes from India and China. You can't just flip a switch. Lucas: Exactly. India alone supplies roughly 40 percent of the generics consumed in the US, and China dominates active pharmaceutical ingredient production — APIs — which are the chemical building blocks. So this tariff targets the whole supply chain, not just finished pills. Luna: And the timing is interesting. The trade-weighted dollar index hit 120.5 last week. A strong dollar makes imports cheaper, which undercuts the tariff's protective effect. You'd need a really high tariff to overcome that currency advantage. Lucas: That's a sharp point. The strong dollar effectively subsidizes foreign manufacturers. So if the dollar stays strong, the tariff might just get absorbed into margins rather than driving production back. The companies that will feel it most are the big Indian generic players — Sun Pharma, Dr. Reddy's, Aurobindo, Cipla. Their entire business model is built on cost arbitrage. Luna: And for US patients, this could mean higher drug prices. Generics are the safety net — they keep insurance costs down. If tariffs push prices up, that's a direct hit on consumers. Lucas: The administration's argument is that the long-term gain in supply chain resilience outweighs the short-term price increase. We saw during COVID how fragile the API supply chain was — India actually restricted exports of certain drugs. Plus, Iran hawks are pointing to the Strait of Hormuz risk as another reason to diversify. Luna: But building a generic drug factory in the US is not cheap. You need fda approved facilities, skilled labor, environmental compliance. The cost per pill could be two to three times higher than India. Lucas: Right, and the tariff doesn't directly subsidize domestic construction. It just makes imports more expensive. So companies have to decide: absorb the tariff, pass it to consumers, or invest billions in US plants. Most will probably do a mix. But the timeline is tight — four years to build and validate a sterile manufacturing facility is ambitious. Luna: There is a precedent. In 2019, the FDA started prioritizing applications for drugs with only one supplier. And during COVID, the government used the Defense Production Act to fund some API capacity. But that was emergency spending, not a structural shift. Lucas: The interesting angle here is that some us based generic manufacturers could actually benefit. Companies like Lannett or Amneal — they already have domestic plants. They'd face less import competition. But they'd also need to scale up fast to fill the gap, and that takes capital. Luna: So who wins and who loses in this scenario? Short term, the big Indian exporters lose. US consumers lose on price. us based generic makers maybe win. And the supply chain gets a little more redundant, which is good for national security. Lucas: I'd add one more loser: the pharmacy benefit managers and insurers who rely on cheap generics to keep premiums down. If the tariff pushes up costs, that could ripple into overall healthcare spending. The US healthcare system is already under enormous cost pressure. Luna: It also raises a question about innovation. Generics are low-margin. If you squeeze that margin further, does that discourage investment in new generic formulations? Biosimilars, complex generics — those are the future. Lucas: Yeah, the policy seems to focus on simple generics — metformin, atorvastatin, lisinopril. The really complex stuff, like inhalers or injectables, is harder to onshore quickly. So we might see a split: simple pills made in the US, complex drugs still imported. Luna: Before we dive deeper, I want to pause for a second. This kind of analysis — looking at the real trade-offs in policy — is exactly why listeners tell us Fexingo is useful. If these conversations have helped you think through a business decision or just understand a complex issue, consider supporting the show. A couple dollars a month genuinely keeps us ad-free and independent. It's buymeacoffee dot com slash fexingo. Totally optional, but it makes a real difference. Lucas: And we don't run ads, so listener support is what keeps this going. Even a small contribution helps us keep researching and producing episodes like this. Now — back to the tariff story. One thing I haven't mentioned is the WTO angle. Luna: Oh, right. Because tariffs on pharmaceutical products have traditionally been very low under the WTO's Pharmaceutical Agreement, dating back to the Uruguay Round. Lucas: Exactly. That agreement eliminated tariffs on hundreds of drug products among signatories. The US is now proposing to unilaterally raise tariffs — which could trigger retaliation or dispute settlement. India has already signaled they might challenge it at the WTO. Luna: But the current administration has been pretty dismissive of WTO rules. They've already imposed tariffs on steel, aluminum, Chinese goods, and more. The WTO's dispute resolution system is also weakened because the US has blocked judge appointments. Lucas: So the enforcement mechanism is basically broken. Still, it's a political risk. Other countries could impose retaliatory tariffs on US exports — agricultural products, medical devices, things like that. So the pharma tariff doesn't exist in a vacuum. Luna: Let's bring it back to the investor perspective. If I'm looking at a generic drug company's stock, what should I be watching over the next four years? Lucas: First, watch capital expenditure announcements. If Indian companies start announcing US plant construction, that's a sign they're taking the tariff seriously. Second, watch their margin guidance — if they start warning about tariff impacts, the stock could get hit. Third, watch the dollar. If the dollar weakens, the tariff becomes more protective. Luna: And what about the API suppliers? Like Laurus Labs or Divi's Laboratories in India — they supply the raw ingredients. If US companies switch to domestic API, those suppliers lose a major market. Lucas: That's a huge risk. China is the dominant API producer — about 80 percent of the world's API comes from China. India is also a major producer. If the US starts building its own API capacity, it will take years and billions of dollars. But the tariff could accelerate that. Luna: So we're really talking about a multi-year transformation of a deeply globalized industry. And it's happening alongside other trade tensions — tariffs on Chinese goods, on European goods, on semiconductors. It's part of a broader decoupling. Lucas: Exactly. This isn't just about drugs. It's about the US trying to rebuild self-sufficiency in critical sectors. The question is whether four years is enough time, and whether the private sector will actually invest. I'm skeptical that the 2028 deadline will hold — we'll probably see delays and exemptions. Luna: But the direction is clear. The era of free trade in pharmaceuticals is ending. And that has implications for drug prices, public health, and global inequality. Lucas: One last data point: the US trade deficit in goods and services widened to nearly 78 billion dollars in May, up from 55 billion. The administration sees tariffs as a way to narrow that deficit. But pharmaceuticals are a small slice of that — the bigger drivers are electronics, oil, and autos. Luna: Still, it's a symbolic target. Everyone takes medicine. So it's politically potent. And the 2028 timeline conveniently aligns with the next presidential term, so the current administration can claim a long-term vision without immediate disruption. Lucas: Right. And that's the cynic's view. The optimist would say: this is a necessary push to fix a vulnerability we've ignored for decades. Realistically, the outcome will be somewhere in between — some onshoring, but a lot of loopholes and delays. Luna: I think that's where we land. A big policy idea, a lot of uncertainty, and a lot of moving parts. We'll be watching. Lucas: We'll be watching. And we'll keep you posted as the details emerge. For now, thanks for listening, and we'll talk to you next time.